Is there an antipsychotic medication available in a gel formulation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Antipsychotic Gel Formulations

No antipsychotic medication is currently available in a gel formulation for clinical use. The available evidence discusses only experimental gel formulations in research settings, not approved products.

Current Antipsychotic Formulations

The established antipsychotic formulations recommended in clinical guidelines include 1:

  • Oral preparations (tablets, orally disintegrating tablets)
  • Depot/long-acting injectable preparations (intramuscular or subcutaneous)
  • Parenteral formulations (intramuscular, intravenous, subcutaneous for acute use)

Guidelines specifically recommend that patients on long-term antipsychotic treatment be given adequate information and encouraged to choose between oral and depot preparations to improve adherence 1.

Experimental Gel Research (Not Clinically Available)

While gel formulations have been investigated in research settings, these are not approved or available for clinical use:

  • Haloperidol gel: Small molecule gelling agent (SMGA) gels were developed experimentally for transdermal delivery of haloperidol, showing successful skin permeation in laboratory studies 2. This remains purely experimental.

  • Clozapine sol-gel: An intranasal poloxamer-based clozapine sol-gel has been studied in rats, showing promising brain delivery with minimal peripheral distribution 3. This is in early research phases only.

  • Transdermal formulations: Various antipsychotics (aripiprazole, asenapine, blonanserin, chlorpromazine, haloperidol, olanzapine, quetiapine, risperidone) have been investigated as transdermal gels, creams, and patches 4. Only blonanserin transdermal patch has been approved (in Japan), but this is a patch, not a gel.

Clinical Implications

For practical clinical use, no gel formulation should be prescribed or expected. When adherence is a concern or alternative routes are needed, the evidence-based options are 1, 5:

  • Long-acting injectable antipsychotics (preferred for adherence issues)
  • Orally disintegrating tablets
  • Liquid formulations (where available)
  • Parenteral formulations for acute situations 6

The research on gel formulations represents potential future developments but has no current clinical application.

References

2
Research

SMGA gels for the skin permeation of haloperidol.

Journal of controlled release : official journal of the Controlled Release Society, 2005

Related Questions

Which atypical antipsychotic medications are available as long‑acting injectable formulations?
What are the practical patient education points for long‑acting injectable (LAI) antipsychotic options, including their indications, side effects, risks, and benefits?
A 10‑day postpartum woman presents with dysuria and a urine culture growing mixed microbiota >100,000 CFU/mL; how should this be managed?
In a 10‑month‑old infant with a slightly indented coronal suture, normal fontanelles, and appropriate head growth, what is the appropriate next step in management?
What is the appropriate 10‑day antibiotic regimen for a patient undergoing ENT follow‑up after image‑guided fine‑needle aspiration/biopsy, assuming no documented β‑lactam allergy?
Can supraventricular tachycardia (SVT) present in an 18-year-old female who experiences palpitations while taking a hot shower?
What are the typical symptoms of a sickle cell crisis?
What is the appropriate initial evaluation and management for acute colitis?
Should a 68-year-old woman with a 4-day new-onset crown-region headache (8/10) and intermittent lower-extremity weakness be evaluated urgently for a possible intracranial cause?
What is the appropriate treatment for varicella‑zoster virus (VZV) pneumonitis?
Is my 6‑year‑4‑month‑old daughter, who is 131.5 cm tall and growing about 7 cm per year, reaching roughly 73 % of her predicted adult height of 180 cm ± 8 cm, showing normal growth or does she require further evaluation?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.